Summary
Retinoblastoma binding protein 1 (RBP-1) is a 143-kDa nuclear phosphoprotein that promotes cell growth by inhibiting the product of retinoblastoma tumour suppressor gene (pRB). We recently found that RBP-1 contains KASIFLK, a heptameric peptide (250–256) recognized by human antibodies and overexpressed by breast cancer cells. In the present study, we demonstrate that human T-cells stimulated with RBP-1 decameric peptides containing KASIFLK can kill human breast cancer cells. These decamers, GLQKASIFLK (247–256) and KASIFLKTRV (250–259), have anchor motifs for both HLA-A2 and HLA-A3. Peripheral blood lymphocytes from 41 normal donors were stimulated by these peptides in culture media containing 15 IU ml–1 interleukin-2, 25 IU ml–1 interleukin-7 and 500 IU ml–1 granulocyte–macrophage colony-stimulating factor. Cytotoxic activity of the T-cells was assessed against autologous B lymphoblastoid cells pulsed with each peptide. Stimulation by GLQKASIFLK generated specific cytotoxic T lymphocyte (CTL) lines from HLA-A2, A3 donors, HLA-A2 donors and HLA-A3 donors. Stimulation with KASIFLKTRV generated specific CTL lines from HLA-A2 donors. No HLA-A2–, A3– CTL line showed specific cytotoxicity against these target cells. These CTL lines were also cytotoxic against HLA-A2 and HLA-A3 breast cancer cells but not against normal fibroblastoid cell lines, normal epidermal cell lines, or a melanoma cell line. RBP-1 peptide antigens may be of clinical significance as a potential peptide vaccine against human breast cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bookstein, R, Shew, JY, Chen, PL, Scully, P & Lee, WH (1990). Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712–715.
Boon, T, Cerottini, JC, Van den Eynde, B, Van der Bruggen, P & Van Pel, A (1994). Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337–365.
Cao, J-N, Gao, T, Giuliano, AE & Irie, RF (1999). Recognition of an epitope of a breast cancer antigen by human antibody. Breast Cancer Res Treat 53: 279–290.
Celis, E, Fikes, J, Wentworth, P, Sidney, J, Southwood, S, Maewal, A, Del Guercio, M-F, Sette, A & Livingston, B (1994a). Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol 31: 1423–1430.
Celis, E, Tsai, V, Crimi, C, De Mars, R, Wentworth, PA, Chesnut, RW, Grey, HM, Sette, A & Serra, HM (1994b). Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105–2109.
Defeo-Jones, D, Huang, PS, Jones, RE, Haskell, KM, Vuocolo, GA, Hanobik, MG, Huber, HE & Oliff, A (1991). Cloning of cDNA for cellular proteins that bind to the retinoblastoma gene product. Nature 352: 251–254.
Fattaey, AR, Helin, K, Dembski, MS, Dyson, N, Harlow, E, Vuocolo, GA, Hanobik, MG, Haskell, KM, Oliff, A, Defeo-Jones, D & Jones, RE (1993). Characterization of the retinoblastoma binding proteins RBP1 and RBP2. Oncogene 8: 3149–3156.
Germain, RN (1994). MHC-dependent antigen processing and peptide presentation: providing ligands for T-lymphocyte activation. Cell 76: 287–299.
Gnjatic, S, Bressac-de Paillerets, B, Guillet, JG & Choppin, J (1995). Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 25: 1638–1642.
Heemels, MT & Ploegh, H (1995). Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64: 463–491.
Heskcth, R (ed) (1997). The Oncogene and Tumour Suppressor Gene Facts Book, 2nd edn, pp 466–475. Academic Press: London
Hoon, DSB, Okamoto, T, Wang, HJ, Elashoff, R, Nizze, JA, Foshag, LJ, Gammon, G & Morton, DL (1998). Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?. J Clin Oncol 16: 1430–1437.
Huang, S, Lee, WH & Lee, EY (1991). A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. Nature 350: 160–162.
Kaelin, WG Jr, Pallas, DC, DeCaprio, JA, Kaye, FJ & Livingston, DM (1991). Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64: 521–532.
Kaelin, WG Jr, Krek, W, Sellers, WR, DeCaprio, JA, Ajchenbaum, F, Fuchs, CS, Chittenden, T, Li, Y, Farnham, PJ, Blanar, MA, Livingston, DM & Flemington, EK (1992). Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70: 351–364.
Kawakami, Y, Eliyahu, S, Aakaguchi, K, Robbins, PF, Rivoltini, L, Yanelli, JR, Appela, E & Rosenberg, SA (1994). Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A-2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347–352.
Lee, EYP, To, H, Shew, JY, Bookstein, R, Scully, P & Lee, WH (1988). Inactivation of the retinoblastoma susceptibility gene in human breast cancer. Science 241: 218–221.
Lee, WH, Bookstein, R, Hong, F, Young, LJ, Shew, JY & Lee, EYP (1987). Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394–1399.
Morioka, N, Kikumoto, Y, Hoon, DSB, Morton, DL & Irie, RF (1994). A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 153: 5650–5658.
Nijman, HW, Van der Burg, SH, Vierboom, MPM, Houbiers, JGA, Kast, WM & Melief, CJM (1994). p53, a potential target for tumor-directed T cells. Immunol Lett 40: 171–178.
Otterson, GA, Kratzke, RA, Lin, AY, Johnson, PG & Kaye, FJ (1993). Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites. Oncogene 8: 949–957.
Peace, DJ, Smith, JW, Chen, W, You, SG, Cosand, WL, Blake, J & Cheever, MA (1994). Lysis of ras oncogen-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 179: 473–479.
Peoples, GE, Yoshino, I, Douville, CC, Andrews, JVR, Goedegebuure, PS & Eberlin, TJ (1994). TCR V beta3+ and V beta6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 152: 4993–4999.
Rammensee, H-G, Friede, T & Stevanovic, S (1995). MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178–228.
Rivoltini, L, Kawakami, Y, Sakaguchi, K, Southwood, S, Sette, A, Robbins, PF, Marincola, FM, Salgaller, ML, Yannelli, JR, Appella, E & Rosenberg, SA (1995). Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154: 2257–2265.
Sidney, J, Grey, HM, Kubo, RT & Sette, A (1996). Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17: 261–266.
Takahashi, T, Irie, RF, Morton, DL & Hoon, DSB (1997a). Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. Cell Immunol 178: 162–171.
Takahashi, T, Irie, RF, Nishinaka, Y & Hoon, DSB (1997b). 707-AP peptide recognized by human antibody induces HLA-A2 restricted CTL killing of melanoma. Clin Cancer Res 3: 1363–1370.
Traversari, C, Van der Bruggen, P, Luescher, IF, Lurquin, C, Chomez, P, Val Pel, A, De Plaen, E, Amar-Costesec, A & Boon, T (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176: 1453–1457.
Van Elsas, A, Nijman, HW, Van der Minne, CE, Mourer, JS, Kast, WM, Melief, CJM & Schrier, PI (1995). Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A *0201. Int J Cancer 61: 389–396.
Wiman, KG (1993). The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J 7: 841–845.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Takahashi, T., Cao, J., Hoon, D. et al. Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer. Br J Cancer 81, 342–349 (1999). https://doi.org/10.1038/sj.bjc.6690698
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690698